Evidence map›Paper›PMID 39292377›Full record

ArticleInternational journal of hematology2024

Newly diagnosed multiple myeloma with bleeding and coagulation abnormalities caused by a thrombin-inhibiting substance.

Fumiya Ohara, Atsuo Suzuki, Nobuaki Suzuki, Takeshi Kanematsu, Shuichi Okamoto, Shogo Tamura, Hitoshi Kiyoi, Tadashi Matsushita, Akira Katsumi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fumiya OharaDepartment of Hematology, National Center for Geriatrics and Gerontology, 7-430 Morioka-Cho, Obu, Aichi, 474-8511, Japan.
Atsuo SuzukiDepartment of Medical Technique, Nagoya University Hospital, Nagoya, Japan.
Nobuaki SuzukiDepartment of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
Takeshi KanematsuDepartment of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.
Shuichi OkamotoDepartment of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.
Shogo TamuraDepartment of Clinical Laboratory Science, Faculty of Health Sciences, Hokkaido University, Sapporo, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tadashi MatsushitaDepartment of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
Akira KatsumiDepartment of Hematology, National Center for Geriatrics and Gerontology, 7-430 Morioka-Cho, Obu, Aichi, 474-8511, Japan. katsumi@ncgg.go.jp.ORCID http://orcid.org/0000-0003-2411-0522

Funding

Japan Health Research Promotion Bureau 2022-young researcher-10JSPS KAKENHI 22K08518Research Funding of Longevity Sciences 22-10
6 · The paper itself

Abstract

Approximately 7% of patients with newly diagnosed multiple myeloma (MM) experience bleeding complications with varying causes, but few reports have described these complications. Here we report the case of a patient with newly diagnosed MM who presented with a bleeding tendency and various coagulation abnormalities. Chromogenic assays, thrombin time, and reptilase time revealed the presence of a thrombin-inhibiting substance that inhibited release of fibrinopeptide A from fibrinogen. The coagulation abnormalities improved after treatment with daratumumab, lenalidomide, and dexamethasone. As the thrombin inhibition mechanism remains unclear, no previous studies have reported recent treatment outcomes in older patients producing thrombin-inhibiting substances, which can hinder clinical treatment. Therefore, we believe that the diagnosis and the treatment course of this case provide valuable information. Moreover, such case reports provide significant insights into the pathophysiology of bleeding complications associated with MM.

Indexed as

Blood Coagulation DisordersDexamethasoneHemorrhageMultiple MyelomaThrombinAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideAntibodies, MonoclonaldaratumumabDexamethasoneLenalidomideThrombinBleedingChromogenic assaysCoagulation abnormalitiesMultiple myelomaThrombin-inhibiting substance

Identifiers

PMID39292377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.